2022年9月7日

倫敦- 2022年9月7日- Purespring Therapeutics是一家開創性的基因治療公司，專注於改變腎髒疾病的治療方法，今天宣布任命Alice Brown為其首席科學官，立即生效。Alice在先進療法領域有十多年的工作經驗，橫跨大型製藥公司和早期生物技術公司。加入Purespring之前，Alice曾擔任GammaDelta Therapeutics的研究副總裁和基因工程副總裁;隨後，她在Takeda於2022年初收購GammaDelta Therapeutics後，短暫地加入了Takeda Pharmaceuticals的細胞治療創新部門。在gammaelta, Alice建立並領導了研究團隊，負責開發多個細胞治療項目，從發現到完成臨床前開發。她擁有布裏斯托爾大學生物化學學位和博士學位，並在倫敦帝國理工學院進行免疫學博士後研究。Alice將領導Purespring的研究團隊，監督公司治療方案的進展。專注於建立其渠道，公司通過一係列高級任命迅速擴大了其內部團隊。Alice將以首席科學顧問的身份與Purespring的聯合創始人Moin Saleem密切合作，建立Purespring無與倫比的AAV基因治療慢性腎髒疾病的管道。Purespring的首席執行官Richard Francis說:“我們的目標是徹底改變腎髒疾病的治療，我們正在快速前進，其中的基石是組建正確的團隊。 With decades of work on the podocyte, Professor Moin Saleem is a world leader in gene therapy for the kidney and his work has been critical to establishing Purespring. Combining this with Alice’s expertise in moving ATMPs through research and into the clinic, we are in the best possible position to move our innovative treatments closer to people suffering from kidney diseases.” Prof. Moin Saleem, Co-founder and Chief Scientific Advisor of Purespring, said: “Over the last year, we have made tremendous progress in our preclinical work at Purespring. Expanding our in-house capabilities is a vital step in shifting our focus towards the clinic and Alice is a critical part of this. With an impressive track record working within similar-stage companies, I believe Alice is well positioned to lead the research team in this next phase of Purespring’s development, and I look forward to working with her.” Alice Brown, Chief Scientific Officer of Purespring, commented: “Purespring is providing leadership in innovation which has been sorely lacking in the kidney space through its approach to using AAV therapy to target the podocyte. I can’t think of a more exciting company to work for at the moment and it’s a privilege to be working with Professor Moin Saleem, who has done so much to advance AAV gene therapy in the kidney. I am thrilled to be working with such a strong team.” - ENDS - About Purespring Purespring is the first company to treat kidney diseases by directly targeting the podocyte, a specialised kidney cell implicated in many kidney diseases, through AAV gene therapy. Headed by former Sandoz CEO, Richard Francis, Purespring was founded on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, where he heads a world leading group researching glomerular diseases. Purespring seeks to advance gene therapies for the treatment of both monogenic and non-monogenic chronic renal diseases that are currently poorly addressed with existing treatments. The company also has a proprietary in-vivo pipeline engine, FunSel, which is a library of all biological factors that could be candidates for gene therapy, combined with a screening method to evaluate these factors in disease models. FunSel allows Purespring to discover new gene therapy candidates across all indications, unconstrained by genetics, to find the right candidate to make the best therapy. An initial £45 million commitment to Purespring from Syncona Ltd is enabling Purespring to progress its assets to the clinic. Syncona’s Chief Investment Officer, Chris Hollowood, serves as Chairman. For more information please visit: purespringtx.com and follow us on LinkedIn .